298 related articles for article (PubMed ID: 27423423)
41. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
42. Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profiles.
Adir Y; Tirman S; Abramovitch S; Botbol C; Lutaty A; Scheinmann T; Davidovits E; Arbel I; Davidovits G; Schneer S; Shteinberg M; Peretz Soroka H; Tirosh R; Patolsky F
Cancer Immunol Immunother; 2018 Jul; 67(7):1135-1146. PubMed ID: 29785657
[TBL] [Abstract][Full Text] [Related]
43. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
[TBL] [Abstract][Full Text] [Related]
44. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers.
Moreno P; Jiménez-Jiménez C; Garrido-Rodríguez M; Calderón-Santiago M; Molina S; Lara-Chica M; Priego-Capote F; Salvatierra Á; Muñoz E; Calzado MA
Mol Oncol; 2018 Oct; 12(10):1778-1796. PubMed ID: 30099851
[TBL] [Abstract][Full Text] [Related]
45. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
[TBL] [Abstract][Full Text] [Related]
46. Erythrocyte fatty acids as potential biomarkers in the diagnosis of advanced lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer.
de Castro J; Rodríguez MC; Martínez-Zorzano VS; Sánchez-Rodríguez P; Sánchez-Yagüe J
Am J Clin Pathol; 2014 Jul; 142(1):111-20. PubMed ID: 24926094
[TBL] [Abstract][Full Text] [Related]
47. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis.
Chen X; Hu Z; Wang W; Ba Y; Ma L; Zhang C; Wang C; Ren Z; Zhao Y; Wu S; Zhuang R; Zhang Y; Hu H; Liu C; Xu L; Wang J; Shen H; Zhang J; Zen K; Zhang CY
Int J Cancer; 2012 Apr; 130(7):1620-8. PubMed ID: 21557218
[TBL] [Abstract][Full Text] [Related]
48. A metabolomic approach to lung cancer.
Hori S; Nishiumi S; Kobayashi K; Shinohara M; Hatakeyama Y; Kotani Y; Hatano N; Maniwa Y; Nishio W; Bamba T; Fukusaki E; Azuma T; Takenawa T; Nishimura Y; Yoshida M
Lung Cancer; 2011 Nov; 74(2):284-92. PubMed ID: 21411176
[TBL] [Abstract][Full Text] [Related]
49. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
Neumann JM; Freitag H; Hartmann JS; Niehaus K; Galanis M; Griesshammer M; Kellner U; Bednarz H
J Cancer Res Clin Oncol; 2022 Feb; 148(2):351-360. PubMed ID: 34839410
[TBL] [Abstract][Full Text] [Related]
50. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
51. Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC.
Zheng CX; Zhao SX; Wang P; Yu HM; Wang CF; Han B; Su B; Xiang Y; Li XS; Li SX; Ma QY; Zhang RX; Wan HY; Song HD
Oncol Rep; 2009 Nov; 22(5):1057-61. PubMed ID: 19787221
[TBL] [Abstract][Full Text] [Related]
52. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
[TBL] [Abstract][Full Text] [Related]
53. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
[TBL] [Abstract][Full Text] [Related]
54. Metabolomic prediction of endometrial cancer.
Bahado-Singh RO; Lugade A; Field J; Al-Wahab Z; Han B; Mandal R; Bjorndahl TC; Turkoglu O; Graham SF; Wishart D; Odunsi K
Metabolomics; 2017 Dec; 14(1):6. PubMed ID: 30830361
[TBL] [Abstract][Full Text] [Related]
55. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
[TBL] [Abstract][Full Text] [Related]
56. Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis.
Zhang X; Zhu X; Wang C; Zhang H; Cai Z
Oncotarget; 2016 Sep; 7(39):63437-63448. PubMed ID: 27566571
[TBL] [Abstract][Full Text] [Related]
57. Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.
Roś-Mazurczyk M; Wojakowska A; Marczak Ł; Polański K; Pietrowska M; Polanska J; Dziadziuszko R; Jassem J; Rzyman W; Widlak P
Acta Biochim Pol; 2017; 64(3):513-518. PubMed ID: 28803255
[TBL] [Abstract][Full Text] [Related]
58. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study.
Poli D; Carbognani P; Corradi M; Goldoni M; Acampa O; Balbi B; Bianchi L; Rusca M; Mutti A
Respir Res; 2005 Jul; 6(1):71. PubMed ID: 16018807
[TBL] [Abstract][Full Text] [Related]
59. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer.
Li R; Todd NW; Qiu Q; Fan T; Zhao RY; Rodgers WH; Fang HB; Katz RL; Stass SA; Jiang F
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):482-7. PubMed ID: 17255269
[TBL] [Abstract][Full Text] [Related]
60. Improving lung cancer prognosis assessment by incorporating synthetic minority oversampling technique and score fusion method.
Yan S; Qian W; Guan Y; Zheng B
Med Phys; 2016 Jun; 43(6):2694-2703. PubMed ID: 27277016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
